Cytomegalovirus-Specific Immunotherapy for Glioblastoma Treatments
- PMID: 35929110
- PMCID: PMC9353163
- DOI: 10.14791/btrt.2022.0010
Cytomegalovirus-Specific Immunotherapy for Glioblastoma Treatments
Abstract
Over the last two decades, numerous studies have investigated the presence of human cytomegalovirus (CMV) within glioblastoma or gliomas; however, the results are severely conflicting. While a few researchers have suggested the potential benefits of cytotoxic T lymphocyte or dendritic cell-based vaccines for recurrent or newly diagnosed glioblastoma patients, several studies did not at all agree with the existence of CMV in glioblastoma cells. In this review, we summarized the conflicting results and issues about the detection of CMV in glioblastoma or glioma patients. We also provided the clinical data of published and unpublished clinical trials using CMV-specific immunotherapy for glioblastomas.
Keywords: Adoptive cell transfer; Cancer vaccines; Cytomegalovirus; Glioblastoma; Immunotherapy.
Copyright © 2022 The Korean Brain Tumor Society, The Korean Society for Neuro-Oncology, and The Korean Society for Pediatric Neuro-Oncology.
Conflict of interest statement
The authors have no potential conflicts of interest to disclose.
References
-
- Lau SK, Chen YY, Chen WG, Diamond DJ, Mamelak AN, Zaia JA, et al. Lack of association of cytomegalovirus with human brain tumors. Mod Pathol. 2005;18:838–843. - PubMed
-
- Poltermann S, Schlehofer B, Steindorf K, Schnitzler P, Geletneky K, Schlehofer JR. Lack of association of herpesviruses with brain tumors. J Neurovirol. 2006;12:90–99. - PubMed
-
- Cimino PJ, Zhao G, Wang D, Sehn JK, Lewis JS, Jr, Duncavage EJ. Detection of viral pathogens in high grade gliomas from unmapped next-generation sequencing data. Exp Mol Pathol. 2014;96:310–315. - PubMed
